Takeaways: The acquisition turns Jamieson into Kirin’s North American foundation alongside Blackmores and FANCL, creating a multi‑brand global preventative health portfolio that can leverag...
Takeaways: By combining a TSXV listing with a Health Canada-accepted ANDS for a domestically made generic Ozempic, Vimy is positioning itself to compete in a fast-growing, high-value GLP-1 marke...
Takeaways: Jupiter’s ALA-002 deal gives it a high-upside, FDA-designated NCE asset in the emerging U.S. psychedelic therapeutics space, expanding the company from one CNS program to two clinical...
Takeaways: Septa’s acquisition of CeeNU from Bristol Myers Squibb turns it into a supply‑critical oncology player in Canada, securing an essential chemotherapy that has faced...
Takeaways The Teva Canada–Samsung Bioepis deal makes Opuviz (aflibercept biosimilar to Eylea) a commercially available, lower‑cost alternative in Canada’s wet AMD, DME, and retinal vein occlusio...
Takeaways: SteriMax’s acquisition of Andone broadens its growth runway beyond injectables into two adjacent, higher-diversification markets, medical devices and veterinary, so the main mark...
Takeaways: Expanded Canadian partnership positions Organon as the exclusive commercialization partner for Samsung Bioepis’s ustekinumab biosimilar Pyzchiva (Stelara reference), creating a six-pr...
Takeaways: UM171 was discovered at Université de Montréal, so this deal keeps a Canadian‑origin innovation tied to a Canadian commercial partner, aligning with domestic priorities around life‑sc...
Takeaways: This acquisition turbocharges Hims & Hers’ Canada growth by giving it a ready-made weight-management business and local provider network, while it becomes the first Canadian...
Takeaways: AbbVie is doubling down on Canada as a discovery hub by becoming the founding sponsor of BioLabs University of Toronto, a ~40,000 sq. ft shared lab at MaRS t...
